Vicki Morrison
Hematology & Oncology · Minneapolis, MNNPI 1891894424
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $229,933 of the $354,430 with a category attached, or 64.9%. 16 manufacturers reported payments, led by Bristol Myers Squibb at 36.9% of the total. Reporting peaked in 2019 at $78,794 and has fallen 86.3% since, to $10,799 in 2025. Among hematology & oncology clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 332 payments — averaging $1067.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$131K
- Lilly USA, LLC$91K
- E.r. Squibb & Sons, L.L.C.$52K
- Seagen Inc.$20K
- Gilead$16K
- Exelixis Inc.$8K
- plus $36K from 10 others
Across 30 payments — averaging $9390.45 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$252K
- Genentech, Inc.$30K
- TG Therapeutics, Inc.$250
What the payments were for
- Consulting fees$54,85515%
- Speaking & faculty fees$229,93365%
- Travel & lodging$66,27119%
- Food & beverage$3,3361%
- Education$360%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 100 | $130,920 |
| Lilly USA, LLC | 88 | $91,403 |
| E.r. Squibb & Sons, L.L.C. | 46 | $51,792 |
| Seagen Inc. | 16 | $20,150 |
| Gilead | 21 | $16,140 |
| Exelixis Inc. | 14 | $7,839 |
| Genentech USA, Inc. | 5 | $6,010 |
| Amgen | 7 | $5,280 |
| Epizyme, Inc. | 4 | $5,163 |
| Merck | 4 | $5,000 |
| AstraZeneca | 5 | $4,965 |
| Morphosys, US Inc. | 9 | $4,587 |
| Astellas Pharma US Inc | 10 | $3,407 |
| Taiho Oncology, Inc. | 1 | $1,563 |
| Daiichi Sankyo Inc. | 1 | $200 |
| Pfizer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$354,430 in reported general payments places this provider in the 95th percentile of 193 hematology & oncology providers in Minnesota.
Other hematology & oncology in Minneapolis
- Mark RedingMinneapolis$519K
- Shilpa GuptaMinneapolis$421K
- Aimee MerinoMinneapolis$161K
- Daniel WeisdorfMinneapolis$64K
- Gautam JhaMinneapolis$55K
- Arpit RaoMinneapolis$46K
- Amit KulkarniMinneapolis$40K
- Gregory VercellottiMinneapolis$34K
- Veronika BachanovaMinneapolis$33K
- Marshall MazepaMinneapolis$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.